Showing results (1531-1540 of 6,509) with videos related to
Sort By:
Pageof 651
Cancer Immunology, Immunotherapy : CII|May 17, 2024
The later-line efficacy and safety of immune checkpoint inhibitors plus anlotinib in EGFR-mutant patients with EGFR-TKI-resistant NSCLC: a single-center retrospective studyXiaoyan Yin, Xinchao Liu, Fei Ren, et al.Cancer Immunology, Immunotherapy : CII|May 14, 2024
Codonopsis pilosula-derived glycopeptide dCP1 promotes the polarization of tumor-associated macrophage from M2-like to M1 phenotypeHongxu Liu, Maojin Yao, Jiaoyan RenCancer Immunology, Immunotherapy : CII|June 4, 2024
Evaluation of the clinical application value of cytokine expression profiles in the differential diagnosis of prostate cancerRongfa Chen, Linna Liu, Hui Chen, et al.Cancer Immunology, Immunotherapy : CII|June 4, 2024
The VISTA/VSIG3/PSGL-1 axis: crosstalk between immune effector cells and cancer cells in invasive ductal breast carcinomaMateusz Olbromski, Monika Mrozowska, Aleksandra Piotrowska, et al.Cancer Immunology, Immunotherapy : CII|June 4, 2024
Identification of an HLA-A*11:01-restricted neoepitope of mutant PIK3CA and its specific T cell receptors for cancer immunotherapy targeting hotspot driver mutationsMeiying Shen, Siyin Chen, Xiaojian Han, et al.Cancer Immunology, Immunotherapy : CII|June 4, 2024
MB2033, an anti-PD-L1 × IL-2 variant fusion protein, demonstrates robust anti-tumor efficacy with minimal peripheral toxicityYoung Jin Park, Suna Kim, Hyoju Bang, et al.Cancer Immunology, Immunotherapy : CII|June 4, 2024
Analysis of PD-L1 promoter methylation combined with immunogenic context in pancreatic ductal adenocarcinomaXinyuan Chen, Shuangni Yu, Jie Chen, et al.Cancer Immunology, Immunotherapy : CII|May 7, 2024
Clinical outcomes of adjuvant nivolumab in resected stage III melanoma: comparison of CheckMate 238 trial and real-world dataJustin C Moser, Shailender Bhatia, Asim Amin, et al.Cancer Immunology, Immunotherapy : CII|May 7, 2024
Long-term survival after anti-PD-1 discontinuation in advanced cutaneous squamous cell carcinoma (cSCC): a proof of concept of benefit of concomitant cemiplimab and radiotherapyBarbara Bailly-Caillé, Romain Levard, Diane Kottler, et al.Cancer Immunology, Immunotherapy : CII|May 1, 2024
Extracellular matrix stiffness and tumor-associated macrophage polarization: new fields affecting immune exclusionKe-Xun Yu, Wei-Jie Yuan, Hui-Zhen Wang, et al.Pageof 651